Noor Lokman

Dr Noor Lokman

Research Officer

School of Medicine

College of Health

Dr Lokman is an emerging leader in the field of ovarian cancer research at the Reproductive Cancer Group (co-led by Dr Carmela Ricciardelli (The University of Adelaide) and Prof Martin Oehler (Royal Adelaide Hospital)). Dr Lokman has received over $0.86M in funding (5 grants as CIA, $231,863) for her work in ovarian cancer research, including 13 awards. To date, Dr Lokman has 40 publications including one book chapter with 1,934 citations (Google Scholar assessed on 20/09/2024, h-index=21).  

Dr Lokman’s research activities include:  

  • Development of a chick chorioallantoic membrane (CAM) assay – Dr Lokman was the first to set up the CAM assay in South Australia using chicken embryos to study ovarian cancer cell invasion and metastasis in vivo (Lokman NA et al., Int J Mol Sci, 2012). This assay has been used in collaboration with other researchers in other cancer types (Das R et al., Cancer Res, 2017, Shakya R et al., Oncogene, 2017, Zhu W et al., Cancer Res, 2017 and Lee E et al., Cancers, 2020). Dr Lokman has also written a book chapter on the CAM assay as a model for cancer invasion and metastasis (Lokman NA et al., Animal Biotechnology 2nd edition, 2020).
  • Validation of autoantibodies as biomarkers – Dr Lokman has independently developed and optimised a custom luminex assay for measuring autoantibodies in patient blood samples. This involved testing a large cohort of blood samples collected from Australia and internationally. Ongoing studies will evaluate the performance of these novel biomarkers with CA125 to improve the sensitivity and specificity for early detection of ovarian cancer.
  • Ex vivo patient derived tissue explant assay – Dr Lokman directly assisted in this valuable pre-clinical model for screening novel therapeutics in patient tissue samples. (Ricciardelli C et al. 2018, Cancer Lett), (Lokman NA et al. 2019, Journal of Exp & Clin Can Res), (Rahaman MH et al. 2019, Mol Oncol), (Lokman NA et al. 2019, Cancers) and (Bantie L et al. 2020, Gynecol Oncol).
  • Carboplatin resistant ovarian cancer cell lines – Dr Lokman generated these cell lines with repeated exposure to carboplatin, and these cells are currently used for proteomics, gene expression and functional studies; (Weiland F et al. 2016, J Proteome Res), (Lokman NA et al. 2019, Cancers) and (Wanqi W et al. 2021, Cancer Drug Resist).
  • Spheroids assay – Dr Lokman has optimized and developed a spheroid assay to study ovarian cancer cell lines and primary ovarian cancer cells. (Acland M et al. 2018, Proteomics Clin Appl), (Lokman NA et al. 2019, Cancers) and (Mittal P et al. 2019, Proteomics).
  • Early detection of ovarian cancer – Dr Lokman has the expertise to perform ELISA assay and statistical analysis (logistic regression analysis) to study novel ovarian cancer biomarkers with CA125. (Weiland F et al. Front Oncol, 2019) and (Lokman NA et al. Diagnostics, 2021)
  • Novel therapeutic targets for ovarian cancer – Dr Lokman is currently investigating the functional roles of candidate cancer-related proteins including annexin A2 (Lokman NA et al., Cancer Microenviron, 2011, Lokman NA et al., Oncotarget, 2013, Lokman NA et al Journal of Exp & Clin Can Res, 2019), TGFB1 (Ween MP et al. Int J of Cancer, 2011), hyaluronan (Lokman et al., Cancers, 2019), transketolase (Ricciardelli C et al., Clin and Exp Metastasis, 2013), cytokeratin 5 (Ricciardelli C et al, Oncotarget, 2017), ABCA1 (Wanqi et al. 2021, Cancer Drug Resist), piRNA pathway genes (Lee E et al., Cancers, 2020), and gonadotrophin receptors (Cheung J et al. Int J Mol Sci, 2021). These proteins are implicated in ovarian cancer chemoresistance and are potential markers that may prognosticate patient outcomes.

 

Project 1

Title: Novel therapeutics for ovarian cancer targeting annexin A2

Description: Ovarian cancer caused 207,252 deaths worldwide in 2020. Current treatments consist of surgery followed by chemotherapy, but over 75% of patients relapse and acquire chemotherapy resistance. There is an urgent need for more efficient treatment strategies against ovarian cancer. Our research focuses on understanding the crosstalk between ovarian cancer cells and the tumour microenvironment. Using proteomics approach, we identified annexin A2 to be upregulated by ovarian cancer cells when they interact with the peritoneum, and thereby promoting metastasis. High annexin A2 expression has been associated with poor survival in ovarian cancer patients.

This project will investigate the effects of annexin A2 inhibition in ovarian cancer cell lines and knockdown of annexin A2 expression will be confirm using RT-PCR and western blot. The effects of annexin A2 inhibition will be examine using functional assays including 3D spheroids assays, cell proliferation and apoptosis assay, cell motility and invasion assay and the chick chorioallantoic membrane (CAM) assay. This project will evaluate the efficacy of annexin A2 inhibitors to block ovarian cancer progression and metastasis.

Location: Adelaide Health and Medical Sciences Building, North Terrace

Co-supervisors: Dr Carmela Ricciardelli, Prof Martin Oehler

Research project start: Semester 1 and 2

Available for: Third year and Honours

Date Position Institution name
2015 - ongoing Postdoctoral Fellow in Reproductive Cancer Group University of Adelaide
2014 - 2015 Research Officer in Reproductive Cancer Group University of Adelaide
2009 - 2009 Research Assistant University of Adelaide

Date Type Title Institution Name Country Amount
2014 Award Dean’s Commendation for Doctoral Thesis Excellence The University of Adelaide Australia -
2014 Award Best Early Career Researcher Poster Robinson Research Institute Symposium Australia -
2013 Award High Commended - Student Poster Award Robinson Institute Research Symposium Australia -
2013 Award Vice-Chancellor’s Prize for Best Poster The University of Adelaide Australia -
2012 Award Best Student Poster Award Robinson Institute Research Symposium Australia -
2012 Award Best Student Poster Award Matrix Biology Society of Australia and New Zealand (MBSANZ) Australia -
2009 Award Best Honours Student, Discipline of Obstetrics and Gynecology The University of Adelaide Australia -

Date Institution name Country Title
2010 - 2014 The University of Adelaide Australia Doctor of Philosophy
2009 - 2009 The University of Adelaide Australia Bachelor of Health Sciences (Honours)
2006 - 2008 The University of Adelaide Australia Bachelor of Science (Biotechnology)

Year Citation
2025 Lokman, N. A., Macpherson, A. M., Thompson, A. R., Price, Z. K., Goonetilleke, L., Condina, M. R., . . . Ricciardelli, C. (2025). Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer. British Journal of Cancer, 13 pages.
DOI
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences, 26(17), 8529.
DOI
2025 Wang, W., Lokman, N. A., Barry, S. C., Oehler, M. K., & Ricciardelli, C. (2025). LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance.. Cancer and Metastasis Reviews, 44(1), 23-1-23-23.
DOI Scopus9 WoS9 Europe PMC7
2025 Price, Z. K., Lokman, N. A., Morrison, J., Mhlanga, S. N., Sugiyama, M., Koya, Y., . . . Ricciardelli, C. (2025). Identification of Sphingosine Kinase 1 as a Novel Protein Regulated by High Molecular Weight Hyaluronan in Ovarian Cancer.. J Cell Mol Med, 29(9), e70574.
DOI
2025 Noye, T. M., Mittal, P., Price, Z. K., Fewster, A., Williams, G., Pukala, T. L., . . . Ricciardelli, C. (2025). Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI. International Journal of Molecular Sciences, 26(12), 5893.
DOI
2024 Bandara, V., Niktaras, V. M., Willett, V. J., Chapman, H., Lokman, N. A., Macpherson, A. M., . . . Ricciardelli, C. (2024). Engineered CAR-T cells targeting the non‐functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer. Clinical & Translational Immunology, 13(5), e1512-1-e1512-17.
DOI Scopus7 WoS7 Europe PMC6
2024 Khetan, R., Eldi, P., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Blencowe, A., . . . Albrecht, H. (2024). Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation.. J Ovarian Res, 17(1), 156.
DOI Scopus2 WoS2 Europe PMC2
2023 Arentz, G., Mittal, P., Klingler-Hoffmann, M., Condina, M. R., Ricciardelli, C., Lokman, N. A., . . . Hoffmann, P. (2023). Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer. Cancers, 15(7), 14 pages.
DOI Scopus5 WoS7 Europe PMC5
2023 Khan, S., Lokman, N. A., Oehler, M. K., Ricciardelli, C., & Yool, A. J. (2023). Reducing the Invasiveness of Low- and High-Grade Endometrial Cancers in Both Primary Human Cancer Biopsies and Cell Lines by the Inhibition of Aquaporin-1 Channels. Cancers, 15(18), 4507-1-4507-27.
DOI Scopus1 WoS1 Europe PMC1
2023 Price, Z. K., Lokman, N. A., Sugiyama, M., Koya, Y., Yoshihara, M., Oehler, M. K., . . . Ricciardelli, C. (2023). Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer. Cellular and Molecular Life Sciences, 80(11), 1-18.
DOI Scopus6 WoS6 Europe PMC6
2022 Acland, M., Lokman, N. A., Young, C., Anderson, D., Condina, M., Desire, C., . . . Klingler-Hoffmann, M. (2022). Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations. Cancers, 14(11), 1-24.
DOI Scopus6 WoS7 Europe PMC7
2022 Leung, D., Price, Z. K., Lokman, N. A., Wang, W., Goonetilleke, L., Kadife, E., . . . Ahmed, N. (2022). Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism. Journal of Translational Medicine, 20(1), 556-1-556-23.
DOI Scopus25 WoS27 Europe PMC27
2022 Price, Z. K., Lokman, N. A., Yoshihara, M., Kajiyama, H., Oehler, M. K., & Ricciardelli, C. (2022). Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways. International Journal of Molecular Sciences, 24(1), 696.
DOI Scopus20 WoS20 Europe PMC19
2021 Lee, E., Lokman, N. A., Oehler, M. K., Ricciardelli, C., & Grutzner, F. (2021). A comprehensive molecular and clinical analysis of the piRNA pathway genes in ovarian cancer. Cancers, 13(1), 1-23.
DOI Scopus12 WoS8 Europe PMC9
2021 Cheung, J., Lokman, N. A., Abraham, R. D., Macpherson, A. M., Lee, E., Grutzner, F., . . . Ricciardelli, C. (2021). Reduced gonadotrophin receptor expression is associated with a more aggressive ovarian cancer phenotype. International Journal of Molecular Sciences, 22(1), 71-1-71-21.
DOI Scopus17 WoS18 Europe PMC16
2021 Lokman, N. A., Ricciardelli, C., Stephens, A. N., Jobling, T. W., Hoffmann, P., & Oehler, M. K. (2021). Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics, 11(1), 1-10.
DOI Scopus10 WoS9 Europe PMC8
2021 Wang, W., Lokman, N. A., Noye, T. M., Macpherson, A. M., Oehler, M. K., & Ricciardelli, C. (2021). ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome. Cancer Drug Resistance, 4(2), 485-502.
DOI Scopus20 WoS20 Europe PMC19
2021 Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2021). Erratum to “A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer” (Gynecologic Oncology (2020) 159(3) (827–838), (S0090825820339056), (10.1016/j.ygyno.2020.09.012)). Gynecologic Oncology, 163(1), 215.
DOI
2021 Palasis, K. A., Lokman, N. A., Quirk, B. C., Adwal, A., Scolaro, L., Huang, W., . . . Abell, A. D. (2021). Optical fibre-enabled photoswitching for localised activation of an anti-cancer therapeutic drug. International Journal of Molecular Sciences, 22(19), 10844-1-10844-10.
DOI Scopus9 WoS9 Europe PMC5
2020 Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2020). A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.. Gynecol Oncol, 159(3), 827-838.
DOI Scopus16 WoS18 Europe PMC16
2020 Weiland, F., Lokman, N. A., Klingler-Hoffmann, M., Jobling, T., Stephens, A. N., Sundfeldt, K., . . . Oehler, M. K. (2020). Ovarian Blood Sampling Identifies Junction Plakoglobin as a Novel Biomarker of Early Ovarian Cancer. Frontiers in Oncology, 10(1767), 1-10.
DOI Scopus10 WoS10 Europe PMC13
2019 Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C. (2019). Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. Journal of Experimental and Clinical Cancer Research, 38(1), 10-1-10-12.
DOI Scopus37 WoS34 Europe PMC27
2019 Christensen, M. V., Høgdall, C., Jensen, S. G., Lokman, N., Ricciardelli, C., Christensen, I. J., . . . Høgdall, E. (2019). Annexin A2 and S100A10 as candidate prognostic markers in epithelial ovarian cancer. Anticancer Research, 39(5), 2475-2482.
DOI Scopus14 WoS12 Europe PMC11
2019 Rahaman, M. H., Lam, F., Zhong, L., Teo, T., Adams, J., Yu, M., . . . Wang, S. (2019). Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology, 13(10), 16 pages.
DOI Scopus45 WoS43 Europe PMC40
2019 Lokman, N. A., Price, Z. K., Hawkins, E. K., Macpherson, A. M., Oehler, M. K., & Ricciardelli, C. (2019). 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancers, 11(8), 1-18.
DOI Scopus49 WoS44 Europe PMC37
2019 Mittal, P., Price, Z. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Klingler-Hoffmann, M., & Hoffmann, P. (2019). Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for monitoring of drug response in primary cancer spheroids. Proteomics, 19(21 - 22), e1900146-1-e1900146-4.
DOI Scopus22 WoS20 Europe PMC16
2018 Acland, M., Mittal, P., Lokman, N., Klingler-Hoffmann, M., Oehler, M., & Hoffmann, P. (2018). Mass spectrometry analyses of multicellular tumor spheroids. Proteomics Clinical Applications, 12(3), 1700124-1-1700124-13.
DOI Scopus23 WoS22 Europe PMC19
2018 Ricciardelli, C., Lokman, N., Sabit, I., Gunasegaran, K., Bonner, W., Pyragius, C., . . . Oehler, M. (2018). Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics. Cancer Letters, 421, 51-58.
DOI Scopus42 WoS40 Europe PMC42
2018 Price, Z., Lokman, N., & Ricciardelli, C. (2018). Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers, 10(12), 482-1-482-21.
DOI Scopus73 WoS70 Europe PMC61
2018 Noye, T. M., Lokman, N. A., Oehler, M. K., & Ricciardelli, C. (2018). S100A10 and cancer hallmarks: Structure, functions, and its emerging role in Ovarian cancer. International Journal of Molecular Sciences, 19(12), 16 pages.
DOI Scopus36 WoS34 Europe PMC34
2017 Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., . . . Selth, L. A. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77(4), 1021-1034.
DOI Scopus103 WoS103 Europe PMC91
2017 Ricciardelli, C., Lokman, N., Pyragius, C., Ween, M., Macpherson, A., Ruszkiewicz, A., . . . Oehler, M. (2017). Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. Oncotarget, 8(11), 17819-17832.
DOI Scopus51 WoS49 Europe PMC50
2017 Shakya, R., Tarulli, G., Sheng, L., Lokman, N., Ricciardelli, C., Pishas, K., . . . Callen, D. (2017). Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. Oncogene, 36(31), 4469-4480.
DOI Scopus38 WoS39 Europe PMC36
2017 Zhu, W., Jarman, K., Lokman, N., Neubauer, H., Davies, L., Gliddon, B., . . . Pitson, S. (2017). CIB2 negatively regulates oncogenic signaling in ovarian cancer via sphingosine kinase 1. Cancer Research, 77(18), 4823-4834.
DOI Scopus30 WoS26 Europe PMC26
2016 Lokman, N. A., Pyragius, C. E., Ruszkiewicz, A., Oehler, M. K., & Ricciardelli, C. (2016). Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. Translational Research, 171, 83-95.
DOI Scopus44 WoS40 Europe PMC39
2016 Mittal, P., Klingler-Hoffmann, M., Arentz, G., Winderbaum, L., Lokman, N., Zhang, C., . . . Hoffmann, P. (2016). Lymph node metastasis of primary endometrial cancers: associated proteins revealed by MALDI imaging. Proteomics, 16(11-12), 1793-1801.
DOI Scopus27 WoS27 Europe PMC24
2016 Zhang, C., Arentz, G., Winderbaum, L., Lokman, N., Klingler-Hoffmann, M., Mittal, P., . . . Hoffmann, P. (2016). MALDI mass spectrometry imaging reveals decreased CK5 levels in vulvar squamous cell carcinomas compared to the precursor lesion differentiated vulvar intraepithelial neoplasia. International Journal of Molecular Sciences, 17(7), 1088-1-1088-12.
DOI Scopus12 WoS9 Europe PMC11
2016 Weiland, F., Arentz, G., Klingler-Hoffmann, M., McCarthy, P., Lokman, N., Kaur, G., . . . Hoffmann, P. (2016). A novel IEF peptide fractionation method reveals a detailed profile of N-terminal Acetylation in chemotherapy-responsive and -resistant ovarian cancer cells. Journal of Proteome Research, 15(11), 4073-4081.
DOI Scopus8 WoS7 Europe PMC6
2016 Ricciardelli, C., Lokman, N., Ween, M., & Oehler, M. (2016). Ovarian cancer-peritoneal cell interactions promote extracellular matrix processing. Endocrine-Related Cancer, 23(11), T155-T168.
DOI Scopus28 WoS28 Europe PMC21
2015 Ricciardelli, C., Lokman, N., Cheruvu, S., Tan, I., Ween, M., Pyragius, C., . . . Oehler, M. (2015). Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clinical & Experimental Metastasis, 32(5), 441-455.
DOI Scopus64 WoS64 Europe PMC58
2013 Ricciardelli, C., Ween, M., Lokman, N., Tan, I., Pyragius, C., & Oehler, M. (2013). Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. BMC Cancer, 13(476), 1-12.
DOI Scopus80 WoS78 Europe PMC72
2013 Lokman, N., Elder, A., Ween, M., Pyragius, C., Hoffmann, P., Oehler, M., & Ricciardelli, C. (2013). Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget, 4(8), 1199-1211.
DOI Scopus64 WoS57 Europe PMC57
2012 Lokman, N., Elder, A., Ricciardelli, C., & Oehler, M. (2012). Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. International Journal of Molecular Sciences, 13(8), 9959-9970.
DOI Scopus318 WoS295 Europe PMC243
2011 Lokman, N., Ween, M., Oehler, M., & Ricciardelli, C. (2011). The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenvironment, 4(2), 199-208.
DOI Scopus205 WoS192 Europe PMC174
2011 Ween, M., Lokman, N., Hoffmann, P., Rodgers, R., Ricciardelli, C., & Oehler, M. (2011). Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. International Journal of Cancer, 128(7), 1-15.
DOI Scopus62 WoS60 Europe PMC62

Year Citation
2025 Khetan, R., Eldi, P., Lokman, N., Ricciardelli, C., Oehler, M., Blencowe, A., . . . Albrecht, H. (2025). Leveraging GPCR overexpression for personalized nanomedicine: A novel approach in ovarian cancer therapy. In CANCER RESEARCH Vol. 85 (pp. 2 pages). IL, Chicago: AMER ASSOC CANCER RESEARCH.
DOI
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer. In CANCER RESEARCH Vol. 85 (pp. A36). AMER ASSOC CANCER RESEARCH.
DOI
2022 Wang, W., Bandara, V., Lokman, N., Napoli, S., Gundsambuu, B., Oehler, M., . . . Ricciardelli, C. (2022). LGR5 CAR-T cells: A novel potential treatment against high grade serous ovarian cancer.. In CANCER RESEARCH Vol. 82 (pp. 2 pages). LA, New Orleans: AMER ASSOC CANCER RESEARCH.
2022 Wang, W., Bandara, V., Lokman, N., Napoli, S., Gundsambuu, B., Oehler, M., . . . Ricciardelli, C. (2022). LGR5 CAR-T cells: A novel potential treatment against high grade serous ovarian cancer. In CANCER RESEARCH Vol. 82 (pp. 2 pages). LA, New Orleans: AMER ASSOC CANCER RESEARCH.
2019 Lokman, N., Ho, R., Gunasegaran, K., Bonner, W., Oehler, M., & Ricciardelli, C. (2019). All trans retinoic acid promotes apoptosis and inhibits serous ovarian cancer invasion. In CLINICAL & EXPERIMENTAL METASTASIS Vol. 36 (pp. 152). SPRINGER.
2011 Ricciardelli, C., Lokman, N. A., Ween, M. P., Hoffman, P., & Oehler, M. K. (2011). Role of annexin A2 in ovarian cancer metastasis. In CLINICAL & EXPERIMENTAL METASTASIS Vol. 28 (pp. 215). SPRINGER.

Year Citation
2024 Wang, W. J., Bandara, V., Lokman, N. A., Price, Z. K. K., Noye, T. M., Napoli, S., . . . Ricciardelli, C. (2024). CAR-T cells targeting LGR5: An effective treatment for chemotherapy resistant ovarian cancer. Poster session presented at the meeting of Proceedings of the American Association for Cancer Research Annual Meeting (AACR, 2024) as published in Cancer Research. San Diego, California: American Association for Cancer Research.
DOI
2019 Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C. (2019). ANTI-TUMOUR EFFECTS OF ALL-TRANS RETINOID ACID, AN ANNEXIN A2-S100A10 PATHWAY INHIBITOR ON SEROUS OVARIAN CANCER. Poster session presented at the meeting of CLINICAL CANCER RESEARCH. Seattle, WA: AMER ASSOC CANCER RESEARCH.
2015 Lokman, N. A., Elder, A. S. F., Ween, M. P., Pyragius, C. E., Hoffmann, P., Ruszkiewicz, A., . . . Ricciardelli, C. (2015). Annexin A2 a potential prognostic marker for serous ovarian cancer promotes ovarian cancer metastasis. Poster session presented at the meeting of CLINICAL & EXPERIMENTAL METASTASIS. SPRINGER.
WoS1
2015 Ricciardelli, C., Cheruvu, S., Lokman, N. A., Ween, M. P., Tan, I. A., Pyragius, C. E., . . . Oehler, M. K. (2015). Transketolase a protein regulated by ovarian cancer-peritoneal interactions is elevated in omental metastases and regulates serous ovarian cancer proliferation. Poster session presented at the meeting of CLINICAL & EXPERIMENTAL METASTASIS. SPRINGER.
2014 Lokman, N. A., Elder, A. S. F., Ween, M. P., Pyragius, C. E., Hoffmann, P., Ruszkiewicz, A., . . . Oehler, M. K. (2014). ANNEXIN A2 A POTENTIAL PROGNOSTIC MARKER FOR SEROUS OVARIAN CANCER PROMOTES OVARIAN CANCER METATASIS. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. LIPPINCOTT WILLIAMS & WILKINS.
Funding
2024

Lloyd Cox O&G Research Accelerator Grant for MCR

Deciphering novel therapeutic targets to overcome chemoresistance in high grade serous ovarian cancer

CIA: Lokman NA (sole CI)

 Lloyd Cox Research Fund $60,000
2024

Identification of novel proteins associated with high molecular weight hyaluronan signaling in ovarian cancer, International Society for Hyaluronan Sciences (ISHAS) Research Travel and Research Grant

CIA: Ricciardelli C, CIB: Lokman NA, CIC: Price ZK, CID: Oehler MK

 International Society for Hyaluronan Sciences (ISHAS) $4,500
2023

Lloyd Cox 'People Support' funding

CIA: Lokman NA (sole CI)

 Lloyd Cox Research Fund $101,863
2020

RRI Invest for Success Funding ' Targeting annexin A2 in high grade serous ovarian cancer' 

CIA: Lokman NA (sole CI)

 Robinson Research Institute (RRI), The University of Adelaide $30,000
2018-2020

Autoantibody biomarkers for ovarian cancer detection

CIA: Oehler MK, CIB: Hoffmann P, CIC: Lokman NA

 Ovarian Cancer Research Foundation (OCRF), Australia $273,220
2018

Vevo 3100 ultrasound biomicroscope for the Adelaide Biomed city precint

Kathy Gatford, Emilie Corrick, Alison Care, Belinda Di Bartolo, Sarah Robertson, Claire Roberts, Jeremy Thompson, Rebecca Robker, Darryl Russell, Louise Hull, Kerrilyn Diener, John Schjenken, Kylie Dunning, Paul Reynolds, Christina Bursill, Joanne Tan, Stephen Nicholls, Johan Verjans, Ryan O’Hare Doig, Claudine Bonder, Eli Moore, Gordon Howarth, Carmela Ricciardelli, Noor Lokman, Suzanne Mashtoub and Mark Corbett.

Ian Potter Foundation Research Grant

 $360,000
2018

Extracellular Vesicles: Novel Biomarkers for Serous Ovarian Cancer

CIA: Lokman NA, CIB: Macpherson AM, CIC: Bedrikovetsky P, CID: Hoffmann P and CIE: Ricciardelli C

 Robinson Research Institute (RRI), The University of Adelaide $25,000
2016-2017

Targeting hyaluronan to overcome chemoresistance in ovarian cancer

CIA: Lokman NA (sole CI)

 RANZCOG/OvCan Scholarship 2016 $15,000
Scholarships
2014 Robinson Institute, Adelaide, SA, Australia, Travel Grant 2014 $2000
2012 Robinson Institute, Adelaide, SA, Australia, Travel Grant 2012 $1500
2012 2012 Postgraduate Travelling Fellowship, Faculty of Health Sciences, The University of Adelaide $2100
2011

Florey Medical Research Foundation Postgraduate Cancer Research Top-Up Scholarship

 $4000
2010 - 2014

Adelaide Graduate Research Scholarship (AGRS),

The University of Adelaide, SA, Australia (Full time PhD Candidate)

$ 23,500 per annum
2009 Robinson Institute, Adelaide, SA, Australia, Honours Scholarship $4000
2007 - 2008 The Queen Elizabeth Hospital (TQEH) Research Foundation, Vacation Research Scholarship $800

Date Role Research Topic Program Degree Type Student Load Student Name
2025 External Supervisor Development of mesothelial cell-targeted therapy to overcome peritoneal dissemination of ovarian cancer Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Ms Marina Yoshikawa

Date Role Research Topic Program Degree Type Student Load Student Name
2024 - 2024 External Supervisor Development of novel ovarian cancer treatment using CAR-T cells targeting LGR5 Doctor of Philosophy Doctorate Full Time Ms Wanqi Wang
2018 - 2024 External Supervisor The Role of Molecular Weight of Hyaluronan in Ovarian Cancer Stem Cell Signalling Pathways and Chemoresistance Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Miss Zoe Kathleen Price
2018 - 2021 Co-Supervisor The Role of piRNA Pathway Genes in Ovarian and Prostate Cancer Progression Doctor of Philosophy Doctorate Full Time Miss Eunice Hsiu Yee Lee

Date Role Research Topic Location Program Supervision Type Student Load Student Name
2024 - ongoing Co-Supervisor CAR-T cells targeting GPC1 : a novel therapeutic approach against ovarian cancer The University of Adelaide - Honours Full Time Mia Alexopoulos
2022 - 2022 Co-Supervisor CAR-T cell immunotherapy against ovarian cancer using in vitro and ex vivo models The University of Adelaide - Honours Full Time Lizamarie Goonetilleke
2019 - 2019 Co-Supervisor Using CAR-T therapies in in vivo ovarian cancer models The University of Adelaide - Honours Full Time Vasiliki Willett
2018 - 2019 Co-Supervisor CAR-T cell immunotherapy against ovarian cancer using in vitro and ex vivo models The University of Adelaide - Honours Full Time Hayley Chapman
2018 - 2019 Co-Supervisor The role of ABC transporters on ovarian cancer progression and chemoresistance The University of Adelaide - Honours Part Time Wanqi Wang
2018 - 2018 Co-Supervisor The role of gonadotropin receptors in ovarian cancer progression The University of Adelaide - Honours Full Time Janelle Cheung
2017 - 2017 Co-Supervisor Role of hyaluronan in ovarian cancer signaling pathways and chemoresistance The University of Adelaide - Honours Full Time Zoe price
2017 - 2017 Co-Supervisor The role of S100A10 in ovarian cancer progression and chemotherapy resistance The University of Adelaide - Honours Full Time Tannith Noye
2016 - 2016 Co-Supervisor Annexin A2: a therapeutic target to block serous ovarian cancer cell growth and invasion The University of Adelaide - Honours Full Time Rachel Ho

Connect With Me

External Profiles

Other Links